Claritev Corporation Class A Common Stock (CTEV)

FairStock Score: 34/100 — RISKY

Key Financials

Strengths

• Generates $109 million in annual free cash flow (30.2% yield on market cap)

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Altman Z-Score of -0.6 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Claritev Corporation Class A Common Stock is a micro-cap healthcare company valued at $361 million. Revenue stands at $979 million, though the company is currently unprofitable. From a quality standpoint, Claritev shows distressed Altman Z-Score of -0.6 warrants caution. On valuation, the stock is strong 10.1% free cash flow yield. Growth dynamics show revenue growing at 6.2% and profit growth of 41.6%. Our composite FairStock Score of 34/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $109 million in annual free cash flow (30.2% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer